To investigate the clinical value of a lower blood pressure (BP) cut-off for Stage 1 (S1) hypertension ( 
Introduction
Among the established somatic and life-style related risk factors for cardiovascular disease (CVD) mortality, the risk of hypertension holds a top rank even surpassing that of smoking. 1 85-89 mmHg stratum as 'high normal'. 2 In contrast, the American College of Cardiology (ACC) and the American Heart Association (AHA) published a new guideline in 2017, defining Stage 1 (S1) hypertension at 130-139 mmHg systolic or 80-89 mmHg diastolic, and Stage 2 (S2) hypertension as the former US and current ECS hypertension definition (> _140/90 mmHg). 3 The ACC/AHA estimated that the proportion of US adult population labelled as having hypertension will increase from 32% to 46%. 3, 4 The reclassification was mainly justified by the SBP Intervention Trial (SPRINT), including 9361 adults over 50-year-old with SBP > _130 mmHg, which showed that lowering SBP to 120 mmHg vs. 130 mmHg led to a substantial relative risk reduction in CVD events and mortality. 5 The reclassification was further supported by two meta-analyses of blood pressure (BP) lowering randomized controlled trials (RCT). 6, 7 However, contrary to these findings, the recent and most extended meta-analysis failed to find a favourable effect of BP lowering in subjects with baseline SBP <140 mmHg for CVD events and mortality outcomes. 8 Apart from highly homogenized patient populations included in RCTs, prospective epidemiological studies have also provided a view into the real-world situation. A meta-analysis of prospective studies supports the 2017 ACC/AHA guideline by showing that 'prehypertension' (defined as SBP 120-139 mmHg) significantly increased the risk of CVD, but not of all-cause mortality. 9 However, the definition of prehypertension used in this study is not in line with the ACC/ AHA reclassification of S1 or S2 hypertension. Given the utmost importance of defining optimal cut-off values for hypertension and the contradictory state of the art, the present investigation used data from the prospective population-based MONICA/KORA study with a random sample of 11 603 participants to assess the proportion of subjects, previously deemed as healthy, who now qualify as hypertensive. Furthermore, considering the adverse effects that labelling people as ill can have, 10 we investigated the occurrence of fatal CVD events based on the 10-year follow-up of participants with S1 and S2 hypertension.
Methods Participants
The study population was taken from the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/Cooperative Health Research in the Region of Augsburg (KORA) cohort study.
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Three independent cross-sectional surveys including 13 427 participants (6725 men and 6702 women aged between 25 and 74-yearold) were conducted in 1984/1985, 1989/1990 , and 1994/1995 as part of the multinational WHO MONICA project. 11 In the current analysis, missing data for depressed mood (N = 939), cholesterol (N = 238), obesity (N = 129), and CVD mortality outcome (N = 26) lead to a final sample of 11 603 participants (5982 men and 5621 women). A dropout analysis revealed that subjects with missing information were older (P < 0.001) compared with subjects with available information.
Assessment of hypertension
Adhering to the WHO MONICA protocol, BP was measured on the right arm in a sitting position using a Hawksley random-zero sphygmomanometer, BP measurements were taken during the clinical interview after approximately half an hour at a 3-min interval. The average readings of the second and third measurement were considered for the analyses. 12 In line with the ACC/AHA Hypertension 
Depressed mood
Depressed mood was assessed using the depression and exhaustion subscale (DEEX), which combines eight items ranging from 0 to 3, leading to a Likert-like scoring range of 0-24. 13 Participants in the top tertile of the depressive symptom distribution stratified by sex were considered as suffering from depressed mood.
History of cardiovascular disease at baseline and high cardiovascular disease risk group
History of CVD at baseline was defined by self-report of myocardial infarction, heart failure, angina, or stroke. Subjects with high CVD risk were defined by having three or more CVD risk factors. 14 
Follow-up and mortality endpoints
Death certificates were obtained from local health departments and coded for the underlying cause of death by a single trained person using the 9th revision of the International Classification of Diseases (ICD-9). In this study, fatal CVD events (ICD-9: 390-459) were used as the endpoint. In the 10-year follow-up (70 148 person years), there were 370 cases of fatal CVD events. For mortality analyses, event times were calculated as time to death. Subjects without events or with loss to follow-up were censored at the time point of the last follow-up.
Statistical analysis Descriptive analyses
The proportion of the population with normal BP, elevated BP, S2 and S1 hypertension at baseline were calculated and Pearson's v 2 test and Wilcoxon rank-sum test were used to assess sex, age, treatment, depressed-mood, and additional risk differences. The S1 and S2 hypertension categories were stratified by sex and age groups (10-years), and significance of the obtained results were assessed using Cochran-Armitage test for trend. Similarly, trends in antihypertensive treatment by age groups were assessed.
Fatal cardiovascular disease events
Mortality rates of CVD adjusted for all primary risk factors were calculated for each BP category. Proportional hazards models were computed to assess the association of elevated BP, S2 and S1 hypertension with CVD mortality, where normal BP was considered as the reference group. Four stepwise multivariate models adjusted for (i) age, sex, survey, (ii) life-style factors, (iii) somatic factors, and (iv) depressed mood were calculated. Model 4 included all primary risk factors. A similar step-wise analysis was conducted for the combined S1 þ S2 hypertension strata vs. normal BP. In order to ensure power of the analyses was at least 80%, a log-rank test was conducted for comparison of survival rates of CVD mortality in participants with S1 or S2 hypertension vs. normal BP. Sensitivity analyses calculated the impact of high CVD risk, relative risk of CVD for treated vs. non-treated participants, and the combined S2 þ S1 variables vs. normal BP. Proportional hazards could be estimated by fitting models stratified by the risk factor categories and plotting the log-log survival curves for each risk factor, which were assessed for parallelism by visual inspection. As severe deviations from parallelism were not observed for any covariates of CVD events, proportional hazards were assumed. Competing risks were accounted for by cumulative incidence functions using Gray's test. Fine and Gray's sub-distribution hazard model was fitted by specifying event of interest, and by censoring for competing events (non-CVD mortality). 15 For all analyses, a P-value <0.05 was considered to be statistically significant. All statistical evaluations were performed using SAS (version 9. 3). The analysis and the description in this manuscript follow the STROBE guidelines for cohort studies.
Results

Baseline characteristics of hypertension
We investigated a population based sample of 11 603 subjects, including 5982 men (51.6%) and 5621 women (48.4%) with a mean age of 47.26 years (±13.3) at baseline. In the total sample, 3914 (33.7%) patients had S2 hypertension. Once the ACC/AHA Guideline's cut-off values for S1 hypertension were applied, an additional 3404 (29.3%) patients were diagnosed with hypertension, almost doubling the prevalence to 7318 (63%).
Sex and age analysis
As shown in Figure 1 , men had higher S2 (41%) and S1 (33%) hypertension in comparison to women (26% for both S2 and S1 hypertension). The prevalence of S2 hypertension increased with increasing age in both sexes, while the prevalence of S1 hypertension decreased with increasing age for men, and also after 45 years for women (P < 0.0001).
Baseline prevalence of cardiovascular disease risk factors
Participants with S2 hypertension presented the most adverse risk factor profile in comparison to other BP groups: they were more likely to be obese, physically inactive, have hypercholesterolaemia, and Type 2 diabetes (Table 1; P < 0.0001 for all baseline characteristics and BP group associations). The prevalence of S1 criterion resulted in a similar, albeit less pronounced adverse risk factor profile. Correspondingly, the 'high CVD risk' category showed a clear doseresponse relationship effect with increasing BP: 7% for normal BP, 10% for elevated BP, 14% for S1, and 21% for S2 hypertensive participants.
Blood pressure lowering treatment
In the S2 hypertension stratum, we identified 948 (24.1%) patients under treatment, while the remaining 2971 (75.9%) did not receive Figure 1 Prevalence of S1 and S2 hypertension in men (n = 5982) and women (n = 5621) of the MONICA/KORA study, by age group. 
Blood pressure and depression
In contrast to the other risk factors, higher BP was associated with having lower depressed-mood (Table 1) . However, S2 patients under treatment, and thus labelled as hypertensive, were the exception to this finding. 16 Among S2 participants, there was a significantly higher prevalence of depressed-mood in treated patients (47%) in comparison to non-treated patients (33%) (P < 0.0001).
Cardiovascular disease mortality
In the primary model, the CVD-specific mortality per 1000 persons within the 10-year follow-up period was 1.61 Figure 3) . Table 2 displays the risk of CVD mortality for participants with S2 hypertension, S1 hypertension, and S1 þ S2 hypertension combined, in comparison to normal BP. In the S2 hypertension stratum, statistical significance for CVD risk was reached in each stepwise-adjustment In contrast, the risk of CVD mortality in both S1 hypertension (Model 4: HR 0.93, 95% CI 0.61-1.44, P = 0.76) and elevated BP strata (Model 4: HR 0.77, 95% CI 0.44-1.34, P = 0.36) vs. normal BP, did not reach statistical significance in any model. Furthermore, combining the S2 and S1 hypertension strata in comparison to normal BP also did not yield significant results between BP >130/80 and CVD mortality in the primary model (HR 1.29, 95% CI 0.89-1.89, P = 0.18).
Competing risks analyses showed that in the primary model, S2 hypertension was associated with CVD mortality risk by HR 1.47 (P = 0.05), S1 hypertension by HR 1.01 (P = 0.95), and elevated BP by HR 0.88 (P = 0.6). The effect of competing events (non-CVD related mortality) had a HR of 1.19 (P = 0.2) in S2 hypertension and HR of 1.01 (P = 0.96) in S1 hypertension.
Sensitivity analyses examining differences of CVD mortality between medically treated vs. non-treated participants with S2 and S1 hypertension were conducted. In the primary model, non-treated S2 participants were at two-fold risk of CVD mortality in comparison to treated S2 participants (HR 2.00, 95% CI 1.14-3.49, P = 0.01), whereas a significant difference of CVD mortality was not found in S1 participants who were treated vs. non-treated (HR 1.33, 95% CI 0.73-2.42, P = 0.35).
An additional sensitivity analyses considering the effect of CVD history showed HR of 1.54 (95% CI 1.03-2.21, P = 0.03) in S2 hypertension, HR 1.03 (0.68-1.57, P = 0.88) in S1 hypertension.
Impact of concurrent cardiovascular disease risk factors
As shown in Table 2 , majority of confounding risk factors had a comparable or higher impact than hypertension on CVD related mortality. For S2 participants, a noteworthy finding was that obesity and depressed mood (HR 1.34, 95% CI 1.05-1.72) showed similar associations to the risk of CVD mortality, demonstrating the high relevance of mental health on CVD related outcomes as comparable to the well-established risk factor of obesity. In comparison, significant associations between depressed mood, obesity, and the risk of fatal CVD events were not found in participants with normal BP. 
Discussion
The implementation of the 2017 ACC/AHA Guideline to a German community-dwelling population in the age range of 25-74 years increased the prevalence of hypertension from 34% to 63%. The increase reported herein is notably higher than the recent estimate by Muntner et al., 4 of a rise in hypertension prevalence from 32% to 46%. Nonetheless, given the substantial burden that such high range of new patients would add to health care systems, is it unclear whether the new cut-off points are medically justified. The present investigation confirms the validity of the S2 hypertension cut-off by showing significant prospective impact in CVD mortality. In contrast, the S1 hypertension cut-off failed to show statistically significant results. However, given the wide boundaries of the CIs, we cannot disprove an increased CVD mortality risk that has been reported in various studies included in previous meta-analyses. Nonetheless, the CVD mortality rates in the S1 hypertension stratum were near the range of elevated BP and normal BP (Take home figure) .
These results presented here are in contrast to a meta-analysis of 20 prospective studies including 1 129 098 participants performed by Huang et al. 9 showing 'prehypertension' (defined as SBP 120-139 mmHg) significantly increased the risk of CVD mortality. However, the significant effect reported in the meta-analysis was driven by four studies, while the remaining 14 studies failed to show significant findings.
The meta-analyses of relevant RCTs also present contradictory findings regarding the optimal BP cut-off for treatment. Our results contradicted the meta-analysis by Ettehad et al. 7 including 612 815 participants from 123 RCTs showing that a SBP reduction of 10 mmHg reduced risk of CVD events and mortality across all SBP strata, independently of baseline SBP. A similar finding was achieved by Bundy et al. 6 where 42 BP lowering RCTs with 144 220 participants were analysed. Within these studies, the goal of BP reduction was set at SBP of 120-124 mmHg and a linear association between mean achieved SBP reductions and CVD risks was evident, including for subjects with 130 mmHg SBP at baseline (HR 0.71). However, the current investigation confirms the most recent and comprehensive meta-analysis by Brunström et al. which included 74 trials with over 300 000 patients. This meta-analysis shows that when baseline SBP is > _140 mmHg, treatment of hypertension is associated with reduced risk of CVD and death. However, at levels <140, treatment did not lead to observed benefits, with an exception only for coronary heart disease patients. 8 The ACC/AHA Guidelines aim to decrease the prevalence of hypertension by introducing preventive BP lowering intervention for the S1 population before they reach S2. At first glance, it sounds sensible to target higher-risk individuals for risk factor modification; however, our findings suggest that it is not the optimal approach. First, room for improvement in adherence to antihypertensive medication remains high: 76% of S2 patients remained untreated, and among the medically treated S2 population, only 13% had successfully lowered BP at baseline. Furthermore, the situation remains concerning after follow-up of higher risk individuals identified at baseline. 
unhealthiest lifestyle and had the highest CVD risk. This also implies that classifying as hypertensive does not lead to a decrease in unhealthy lifestyle factors, and a lower hypertension classification may not have relevance to initiating lifestyle interventions. Hence, the results demonstrate that having the firmly established ECS hypertension guideline did not lead to higher medical treatment or a healthier lifestyle, and it is doubtful whether a new guideline would lead to higher compliance with BP lowering initiatives.
The relative risk analysis conducted in the present investigation shows that S2 hypertension is not the only significant predictor of CVD risk; and in reality, other risk factors are comparable or present even higher risk. In line with previous findings by Ladwig et al., 18 depressed mood is a significant risk factor to consider, leading to a 34% increase in risk of fatal CVD events in the S2 hypertension stratum. However, based on the cross-sectional baseline analysis, participants in the S2 stratum actually had less depressed mood in comparison to other BP groups, with an exception: among those using antihypertensive medication, half also reported having depressed mood, compared with a third of those not using medication. In line with these findings, Herrmann-Lingen et al. 16 showed that a higher BP per se was related to less depression, however patients labelled as hypertensive had more depressive symptoms than those without, partially due to medication and awareness of being ill. Hence, high BP could have a protective effect against depression, as suggested by the decrease in depressed mood, however the substantial risk of depressed mood on CVD events is amplified from an awareness of being ill. Furthermore, labelling has adverse effects on an individual's state of physical and mental health. A review by Pickering shows that diagnoses of hypertension has harmful consequences such as anger, anxiety, depression, deterioration of marital and home life, and worse perception of health in comparison to those without hypertension. 10 The landmark study of this phenomenon, performed by Haynes et al.,
19 includes steelworkers recently diagnosed with hypertension, and reports increased work absenteeism by 80% in the following year. Furthermore, an experimental study by Rostrup et al., 20 involving military recruits in Norway shows hypertension labelling leads to increase in BP at the next medical examination. Similarly, labelling of people within the S1 stratum as hypertensive could possibly result in the adoption of sick roles. 21 
Limitation
A limitation of this prospective study is that direct cause and effect relationships cannot be discerned. Furthermore, although we adjusted for a variety of important confounding variables, we cannot exclude that unknown risk factors may have biased the results. Similarly, the wide age range of the population could contribute to the wide CIs in this study, however, this was in line with the ACC/ AHA guidelines which do not distinguish between different age groups. The strength of the study is the heterogeneity of a large number of subjects randomly drawn from the population and representative of all hypertensive patients in the community-dwelling population and hence in line with the ACC/AHA guidelines, as opposed to target groups with specific conditions in RCTs. Additional strengths were the availability of data on lifestyle and multiple risk factors, which were measured according to a standardized protocol.
Conclusion
The current prospective epidemiological study has provided a view into the real-world situation of S2 and S1 hypertension patients. The authors of this study recommend a shift of focus back towards BP lowering for patients within the S2 hypertension stratum. As is shown, the departure from the previous US and the current ESC guideline has captured a population that presents lower CVDspecific mortality, and statistically insignificant fatal CVD events. However, participants with S1 hypertension may present clinically significant risk factors that is associated to CVD mortality and should not be overlooked by health care workers ( Table 2) . Nevertheless, the burden on the health care system arising from a lower hypertension cut-off may not be justified considering the potential adverse effects.
Funding
The KORA research platform and the KORA Augsburg studies are financed by the Helmholtz Zentrum Munchen, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. This work was additionally supported by the Munich Heart Alliance.
Conflict of interest: none declared.
